Tenggara Ignatius R, Lesmana C Rinaldi, Gani Rino A
Department of Internal Medicine, Atma Jaya University, Jakarta, Indonesia.
Acta Med Indones. 2017 Jul;49(3):220-226.
Hepatitis B is endemic in Indonesia and treatment response need to be monitored during and after antiviral therapy. Liver stiffness measurement and alanine aminotransferase-to-platelet ratio index (APRI) are noninvasive method to detect liver fibrosis available in Indonesia. However, little is known about their ability to evaluate treatment response in chronic hepatitis B (CHB) patients in Indonesia. This study aimed to investigate liver stiffness changes by transient elastography (TE) and APRI before and after one-year oral antiviral treatment in CHB patients and the correlation between TE and APRI.
this study was retrospective cohort on CHB patients in CiptoMangunkusumo Hospital, Jakarta who uderwent treatment between January 2012 and December 2014. Patients received oral antiviral treatment with newer nucleoside analogues (entecavir or telbivudine) for at least one year. TE and APRI were obtained before and after treatment. TE and APRI reductions were analyzed statistically with Spearman's test.
a total of 41 patients were enrolled in this study. Median liver stiffness value was significantly reduced from 10.8 to 5.9 kPa after oral antiviral treatment (p<0.001, Wilcoxon's test). Median APRI was also significantly reduced from 1.13 to 0.43 after treatment (p<0.001, Wilcoxon's test). The correlation between liver stiffness and APRI before treatment was weak (r=0.40), but it was strong after treatment (r=0.73).
the liver stiffness measured with transient elastography and APRI significantly decreased after one year of antiviral treatment in chronic HBV patients. There was a significant correlation between TE and APRI after one year of treatment.
乙型肝炎在印度尼西亚呈地方性流行,抗病毒治疗期间及之后需要监测治疗反应。肝脏硬度测量和丙氨酸转氨酶与血小板比值指数(APRI)是印度尼西亚可用于检测肝纤维化的非侵入性方法。然而,对于它们评估印度尼西亚慢性乙型肝炎(CHB)患者治疗反应的能力知之甚少。本研究旨在调查慢性乙型肝炎患者口服抗病毒治疗一年前后通过瞬时弹性成像(TE)和APRI检测的肝脏硬度变化以及TE与APRI之间的相关性。
本研究是对2012年1月至2014年12月期间在雅加达西托·曼古库苏莫医院接受治疗的慢性乙型肝炎患者进行的回顾性队列研究。患者接受新型核苷类似物(恩替卡韦或替比夫定)口服抗病毒治疗至少一年。在治疗前后获取TE和APRI数据。采用Spearman检验对TE和APRI的降低情况进行统计学分析。
本研究共纳入41例患者。口服抗病毒治疗后,肝脏硬度值中位数从10.8 kPa显著降至5.9 kPa(p<0.001,Wilcoxon检验)。治疗后APRI中位数也从1.13显著降至0.43(p<0.001,Wilcoxon检验)。治疗前肝脏硬度与APRI之间的相关性较弱(r=0.40),但治疗后相关性较强(r=0.73)。
慢性乙肝患者抗病毒治疗一年后,通过瞬时弹性成像测量的肝脏硬度和APRI显著降低。治疗一年后,TE与APRI之间存在显著相关性。